SFI
ABUS icon

Susquehanna Fundamental Investments’s Arbutus Biopharma ABUS Stock Holding History

Susquehanna Fundamental Investments’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-115,295
Closed -$402K – 711
2025
Q1 		$402K Sell
115,295
-87,246
-43% -$291K 0.01% 895
2024
Q4 		$662K Buy
+202,541
New +$745K 0.01% 807
2024
Q2 		$643K Buy
208,152
+105,228
+102% +$316K 0.01% 640
2024
Q1 		$266K Buy
+102,924
New +$267K 0.01% 577

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCP
BlackBarn Capital Partners New York $1.24B AUM 55.98% 1-Year Est. Return

Susquehanna Fundamental Investments's ABUS Position: Q2 2025 in Review

Susquehanna Fundamental Investments sold out of Arbutus Biopharma (ABUS) in Q2 2025, closing a stake of 115,295 shares — an estimated $402K sold.

Susquehanna Fundamental Investments first reported a position in ABUS in Q1 2024 and held it in 4 quarters. The position peaked at $662K in Q4 2024. 162 funds tracked by Wall St. Rank hold ABUS as of Q2 2025.

  • Susquehanna Fundamental Investments reported no remaining Arbutus Biopharma position as of Q2 2025 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 115,295 Arbutus Biopharma shares in Q2 2025, an estimated $402K.
  • Susquehanna Fundamental Investments first reported a position in Arbutus Biopharma in Q1 2024 and held it in 4 quarters.
  • Susquehanna Fundamental Investments's Arbutus Biopharma position peaked at $662K in Q4 2024.
  • 162 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2025.

Based on Susquehanna Fundamental Investments's 13F filing for Q2 2025, filed 14 Aug 2025.